|
|
Article: HGS Licenses Two Targets To Schering-Plough, Fulfills Duties.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Schering-Plough Corp. acquired exclusive rights to two human antibodies derived from Human Genome Sciences Inc.'s technology, thereby completing HGS's obligations to Schering as defined by the Human Gene Therapeutic Consortium.
HGS would receive milestone payments and royalties from products that result from either antibody. Schering-Plough, of Madison, N.J., had options to two therapeutic proteins, one of which it picked up in October 2000, deciding to develop and commercialize a type of interferon. That left Schering-Plough with one protein option.
"Rather than retain [its] additional option, we granted Schering-Plough ...
Related newspaper, magazine, and journal articles:
|
|
Article: HGS Picks Watkins as New Chief Executive
The Washington Post;
November 22, 2004 ;
700+ words
... ... marketer. Watkins replaces William A. Haseltine, the colorful scientist who founded HGS in 1992. Haseltine served as chairman and chief executive ... Argeris N. Karabelas, who succeeded Haseltine as HGS chairman in October. In the late 1990s ...
|
|